Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Ferring Pharmaceuticals |
---|---|
Information provided by: | Ferring Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00116779 |
The purpose of the study is to contribute, along with other such dose-finding studies, to the determination of the most effective treatment regimen for a one month depot injection of degarelix in the treatment of prostate cancer by a rapid and sustained suppression of testosterone.
Condition | Intervention |
---|---|
Prostate Cancer |
Drug: Degarelix |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label, Randomized, Multi-Center, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer Dosed for Thirteen 28-Day Cycles |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Each patient must meet the following inclusion criteria before entry into the study.
Exclusion Criteria:
Any patient meeting one or more of the following exclusion criteria will not be entered into the study.
Study ID Numbers: | FE200486 CS14 |
Study First Received: | June 30, 2005 |
Last Updated: | September 28, 2005 |
ClinicalTrials.gov Identifier: | NCT00116779 |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
Prostate Cancer Androgen ablation therapy |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site |